Navigation Links
BioMS Medical provides corporate update
Date:12/17/2009

Toronto Stock Exchange Symbol: MS

EDMONTON, Dec. 17 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS) today provided the following update on corporate developments:

    Dirucotide Update
    -----------------

The Company has completed its substantive review of the data from the discontinued late-stage trials for dirucotide, its drug candidate for the treatment of multiple sclerosis (MS). BioMS has decided that it will explore a compassionate access and research program with limited financial commitment, but that it will not pursue further late stage clinical trials with dirucotide in MS.

    Strategic Investment
    --------------------

BioMS earlier today announced a $12.0 million strategic investment in Spectral Diagnostics Inc., in exchange for approximately 48% of Spectral's issued and outstanding common shares, once the proposed transaction is completed. BioMS will also support Spectral and its management team in the development of its lead product, Toraymyxin(TM), in the US under a three-year $3 million contract to supply BioMS' management services to Spectral.

"Spectral represents the type of development opportunity that BioMS is seeking and ideally suited for: investment in a late-stage clinical program with a large market opportunity, and the ability to assist in the successful development of a project using our management expertise," said Kevin Giese, President and CEO of BioMS Medical. "BioMS will continue to leverage its resources and management team to pursue additional opportunities to realize shareholder value."

Spectral is a leader in the battle against sepsis. Spectral's Endotoxin Activity Assay (EAA(TM)) is the only FDA cleared assay for the measurement of endotoxin in the bloodstream. With the growing awareness for the role of endotoxemia in sepsis, the EAA(TM) can be used to identify patients, enable therapeutics and monitor treatment.


'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... (PRWEB) March 02, 2015 Outside GC, ... today announced the addition of Debbie Casey as a ... in the healthcare space. , Debbie has ... of which with Fresenius Medical Care North America in ... her extensive experience to work with Outside GC’s growing ...
(Date:2/27/2015)... SUMMERLAND, British Columbia , Feb. 27, 2015 ... ), a leader in synthetic biology, today announced it ... Fruits (OSF), the pioneering agricultural company behind the ... non-browning apple. Through the acquisition, Intrexon expands its food ... appetizing and convenient for consumers while providing economic benefit ...
(Date:2/27/2015)... Scotia (PRWEB) February 27, 2015 ... vaccine and immunotherapy company, today announced that the ... application for Fast Track designation and Phase I ... in conjunction with the mutual co-development agreement signed ... obtained Fast Track designation for the DPX-Survivac. , ...
(Date:2/27/2015)... 2015 FamilyFarms Group is pleased to ... State Line Farms, received the 2015 Tomorrow’s Top Producer ... the age of 35, who has demonstrated excellence in ... to win the Tomorrow's Top Producer Horizon Award. Every ... Top Producer Award and learning from their experiences. It ...
Breaking Biology Technology:Outside GC Expands Healthcare Team 2Intrexon to Acquire Okanagan Specialty Fruits 2Intrexon to Acquire Okanagan Specialty Fruits 3Intrexon to Acquire Okanagan Specialty Fruits 4Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2
... PALO ALTO, Calif., Aug. 28 Avicena ... biotechnology company that,develops central nervous system therapeutics ... announced today that it has signed an,exclusive ... leading,supplier of specialty chemicals to the personal ...
... 128-compliant label,design and printing software solutions to healthcare providers, blood banks ... ... Niceware(R) International, LLC is,excited to announce that ICCBBA, Inc. granted ... labeling,software solutions that support ISBT 128-compliant data structures and bar,codes. ...
... With 3.8 Million Patients ... ... Slightly Accretive to Medco Shareholders in ... 2008, FRANKLIN LAKES, N.J. and WAKEFIELD, Mass., Aug. 28 ,Medco Health ...
Cached Biology Technology:Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds 2Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds 3Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds 4Niceware International Announces Licensed Vendor Status with ICCBBA, Inc. to Provide ISBT 128-compliant Software 2Medco Announces Agreement to Acquire Diabetes Care Leader PolyMedica in Transaction Valued at $1.5 Billion 2Medco Announces Agreement to Acquire Diabetes Care Leader PolyMedica in Transaction Valued at $1.5 Billion 3Medco Announces Agreement to Acquire Diabetes Care Leader PolyMedica in Transaction Valued at $1.5 Billion 4Medco Announces Agreement to Acquire Diabetes Care Leader PolyMedica in Transaction Valued at $1.5 Billion 5Medco Announces Agreement to Acquire Diabetes Care Leader PolyMedica in Transaction Valued at $1.5 Billion 6Medco Announces Agreement to Acquire Diabetes Care Leader PolyMedica in Transaction Valued at $1.5 Billion 7
(Date:2/5/2015)... Conn. , Jan. 26, 2015 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... new corporate website ( http://www.nxt-id.com/ ) as part of ... smart wallet. The Company launched its new consumer website ... Gino Pereira , CEO of NXT-ID said, "Our new ...
(Date:2/5/2015)... DUBLIN , Jan. 28, 2015 Research ... announced the addition of the "Global Biometrics ... Use, Regions and Countries " report to their ... market, Asia-Pacific is anticipated ... by 2015, owing to increasing government spending towards ...
(Date:1/22/2015)... , Jan. 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: ... market in general the State of Washington,s ... for a new enrollment and central issuance system for driver,s ... The project planning and development will start in ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Valid USA Signs Contract For Washington Driver's License Issuance 2
... May 4, 2012 Young men who play volleyball, basketball ... more increase bone mass and might gain protection from developing ... the May issue of the Journal of Bone and ... investigation of its kind, discovered that young men who actively ...
... Sloppy shipping of a donated human retina to an ... loss has inadvertently helped uncover a previously undetected mechanism ... urge review of how millions of dollars are spent ... degeneration called choroidal neovascularization. Working at IU,s ...
... patients are treated with a drug called tamoxifen. The ... the growth signals of this hormone in cancer cells. ... their growth program: They change their behavior and shape, ... invade surrounding tissue. Scientists working with PD (Associate Professor) ...
Cached Biology News:Study: Men who do load-bearing exercise in early 20s may be shielded from osteoporosis 2Study: Men who do load-bearing exercise in early 20s may be shielded from osteoporosis 3Sloppy shipping of human retina leads IU researchers to discover new treatment path for eye disease 2Sloppy shipping of human retina leads IU researchers to discover new treatment path for eye disease 3Sloppy shipping of human retina leads IU researchers to discover new treatment path for eye disease 4MicroRNA controls malignancy and resistance of breast cancer cells 2
Rabbit polyclonal antibody to Glutathione-S-Transferase (GST)...
... Chromatograph/Mass Spectrometer, utilizing many of the ... offers high throughput and excellent productivity, ... ratio. Like the GCMS-QP2010 Plus, the ... for optimum separation, 20 temperature ramps, ...
Chicken polyclonal antibody to Glutathione-S-Transfrease (GST)...
... XS uniquely combines a single-channel sample processing ... 8-channel bulk reagent dispenser all in one ... using disposable pipette tips, the Precision XS ... dispenser is available for transferring larger volumes. ...
Biology Products: